Recent Fundraising Activities Epic Sciences has secured significant funding rounds recently, totaling $48M in Series F and G. This influx of investment indicates growth potential and could be an opportunity to introduce new products or expand market reach.

Key Personnel Additions The hiring of William Kullback as CFO and James Rothman to the board of directors brings strong leadership and industry expertise to Epic Sciences. Leveraging the experience of these key personnel could open doors to collaborations or partnerships with other industry players.

Product Launches Epic Sciences launched DefineMBC, a blood test for metastatic breast cancer diagnosis. This innovative product could be positioned as a solution to unmet needs in the oncology market, creating opportunities for strategic alliances with healthcare providers or pharmaceutical companies.

Technology Stack With a tech stack including MySQL and Bootstrap, Epic Sciences demonstrates a commitment to cutting-edge technology. Leveraging these tools effectively could differentiate the company in a crowded market and attract tech-savvy clients seeking advanced solutions.

Strategic Partnerships Having partnered with leading pharmaceutical companies and cancer centers, Epic Sciences has established a strong network within the healthcare industry. Strengthening these partnerships and exploring collaborations with key players could drive sales growth and market penetration.